ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015
Blood and marrow transplant clinical trials network state of the Science Symposium 2014.
Registry-linked trialAbstract readConference Proceedings
In one paragraph
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03992352 (Composite Health Assessment Risk Model), which is not on this map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)
Who cites it
16 citing papers in PubMed.
- Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.Blood advances · 2023Trial
- Trial
- Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.Blood advances · 2025Observational
- Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.Advances in experimental medicine and biology · 2025Review
- Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.Transplantation and cellular therapy · 2021Review
- Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Hematopoietic Stem Cell Transplantation, Where Have We Come and Where Do We Go.Blood cell therapy · 2020Review
- Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?Current hematologic malignancy reports · 2019Review
- Patient HLA Germline Variation and Transplant Survivorship.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Article
- The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Review
- Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2016Review
- Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- Alternative Donor Transplantation for Acute Myeloid Leukemia.Journal of clinical medicine · 2015Review
- Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age.Leukemia & lymphoma · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Frederick R AppelbaumClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: fappelba@fhcrc.org.
Claudio AnasettiResearch & Clinical Trials, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Joseph H AntinStem Cell Transplants, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harold AtkinsCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Stella DaviesBone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital, Cincinnati, Ohio.
Steven DevineBlood and Marrow Transplant Program, The Ohio State University, Columbus, Ohio.
Sergio GiraltBone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
Helen HeslopAdult Bone Marrow and Stem Cell Transplant Program, Baylor College of Medicine, Houston, Texas.
Ginna LaportMedicine-Blood & Marrow Transplantation, Stanford Hospital and Clinics, Stanford, California.
Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Brent LoganClinical Research Division, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Marcelo PasquiniClinical Research Division, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Michael PulsipherBiostatistics, University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, Utah.
Edward StadtmauerDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
John R WingardHematology Division-Internal Medicine Department, University of Florida, Gainesville, Florida.
Mary M HorowitzClinical Research Division, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MTUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MIntegrative Molecular Epidemiology WorkshopR25CA174664 · NCI · AMERICAN ASSOCIATION FOR CANCER RESEARCH · PI Shelley S Tworoger · 2013 to 2026
$2.8MBMT CTN Core- University of Pennsylvania Abramson Cancer CenterUG1HL069286 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Edward A Stadtmauer · 2017 to 2026
$2.0MMSKCC BMT CTN Renewal U10HL069315 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI GIRALT, SERGIO A · 2011 to 2016
$1.1MBlood & Marrow Clinical Trials Network - Hutchinson Center Core Clinical SitU10HL069246 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI APPELBAUM, FREDERICK · 2011 to 2016
$1.1MA Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCTU10HL069249 · NHLBI · DANA-FARBER CANCER INST · PI ANTIN, JOSEPH H · 2011 to 2016
$1.1MBone Marrow Transplant Clinical NetworkU10HL069286 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI STADTMAUER, EDWARD A · 2011 to 2016
$986kAnti-viral and antileukemic T-cell therapy as prophylaxis after HSCTU10HL108945 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI HESLOP, HELEN E · 2011 to 2016
$954kCore Clinical Consortium for Blood and Marrow Transplant Clinical Trials NetworkU10HL069301 · NHLBI · UNIVERSITY OF FLORIDA · PI WINGARD, JOHN R. · 2011 to 2016
$882kBlood and Marrow Transplant Clinical Trials NetworkU10HL069254 · NHLBI · UNIVERSITY OF UTAH · PI PULSIPHER, MICHAEL A · 2011 to 2016
$839kNCI NIH HHS P01 CA049605NCI NIH HHS R25 CA174664NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069246NHLBI NIH HHS U10 HL069249NHLBI NIH HHS U10 HL069254NHLBI NIH HHS U10 HL069286NHLBI NIH HHS U10 HL069291NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10HL069294NHLBI NIH HHS U10 HL069301NHLBI NIH HHS U10 HL069315NHLBI NIH HHS U10 HL108945NHLBI NIH HHS UG1 HL069286
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bone Marrow TransplantationHematopoietic Stem Cell TransplantationAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCell- and Tissue-Based TherapyChildGenetic TherapyGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteLymphomaMultiple MyelomaMyelodysplastic SyndromesRandomized Controlled Trials as TopicTransplantation ConditioningHematopoietic cell transplantationLeukemiaLymphomaMyeloma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03992352ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.